Magdalena Espinoza
Overview
Explore the profile of Magdalena Espinoza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim M, Espinoza M, Huang Y, Franses J, Zhu H, Hsiehchen D
JAMA Netw Open
. 2025 Feb;
8(2):e2461735.
PMID: 39998829
Importance: Immunotherapies are the preferred frontline treatment for most hepatocellular carcinomas (HCCs), but only a small subset of patients attain complete responses to immunotherapies, resulting in an absence of radiographic...
2.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, et al.
Nat Cancer
. 2024 Mar;
5(7):1121-1129.
PMID: 38528112
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 or its ligand (PD-1/L1) have expanded the treatment landscape against cancers but are effective in only a subset of patients....
3.
Lim M, Muquith M, Miramontes B, Espinoza M, Hsiehchen D
Cancer Res Commun
. 2023 Sep;
3(9):1912-1916.
PMID: 37772995
Significance: Treatment beyond progression with ICIs in patients with HCC is safe and may benefit a subset of patients due to later-onset tumor responses or disease stability. These findings may...
4.
Lim M, Muquith M, Miramontes B, Lee C, Espinoza M, Huang Y, et al.
Hepatology
. 2023 May;
78(6):1755-1762.
PMID: 37254559
Background And Aims: Immunotherapies have altered the treatment paradigm in HCC. Surrogate and modified endpoints are used to assess early success in clinical studies and guide clinical practice. We sought...
5.
Espinoza M, Muquith M, Lim M, Zhu H, Singal A, Hsiehchen D
Gastroenterology
. 2023 Mar;
165(1):286-288.e4.
PMID: 36894034
No abstract available.
6.
Muquith M, Espinoza M, Hsiehchen D
J Gastrointest Cancer
. 2022 Aug;
54(3):982-985.
PMID: 35939228
No abstract available.
7.
Muquith M, Pham T, Espinoza M, Hsiehchen D
JAMA Netw Open
. 2022 Feb;
5(2):e220031.
PMID: 35212754
No abstract available.
8.
Hsiehchen D, Naqash A, Espinoza M, von Itzstein M, Cortellini A, Ricciuti B, et al.
Oncoimmunology
. 2022 Jan;
11(1):2017162.
PMID: 35003896
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE...
9.
Hsiehchen D, Espinoza M, Valero C, Ahn C, Morris L
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34795008
The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility....
10.
Hsiehchen D, Espinoza M, Gerber D, Beg M
Cancer Biol Ther
. 2021 Aug;
22(7-9):455-464.
PMID: 34392779
Circulating tumor DNA (ctDNA) is utilized for molecular profiling of cancers, and is under investigation for a growing number of applications based on the assumption that ctDNA levels faithfully reflect...